About Omacor

Product overview

Your Patient's Omacor Prescription.

Omega-3-acid ethyl esters 90

Omacor is an evidence-based therapy for secondary prevention post-MI and endogenous hypertriglyceridaemia. For hypertriglyceridaemia it is to be used as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: type IV in monotherapy; type IIB/III in combination with statins, when control of triglycerides is insufficient. ¹

Omacor provides 460 mg EPA and 380 mg DHA in a single 1g capsule.

The value of Omacor has been established in a large randomised controlled trial (GISSI-P) with 11,324 patients over three and a half years². In this study, Omacor reduced the relative risk of all-cause mortality by an additional 20% when added to other post-MI therapy (2.1% absolute risk reduction).

The following parameters were also improved by the addition of Omacor to the post-MI therapy used in GISSI-P. ²

• Cardiovascular death relative risk reduction: 30% (2% absolute risk reduction)
• Sudden death relative risk reduction: 45% (1.6% absolute risk reduction)

The survival benefit of Omacor is comparable to other post-MI therapies as demonstrated in other cardiovascular trials such as 4S and the Antiplatelet Trialists' Collaboration.^3,4

Omacor is the only omega-3-containing product licensed for secondary prevention post-MI.

Dosage for secondary prevention post MI is one capsule daily: Rx Omacor 1g od.¹